ImmuneOnco Published Preclinical Research data of IMM0306 in the Leukemia
A few days ago, the research team of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") published the research data of the product IMM0306 in the Leukemia. The peer-reviewed paper is in tittle of "IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα , exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells" . The paper is open now for full text downloading at the journal website.
Dr. Tian, Wenzhi, founder and chairman of ImmuneOnco, said:
"I am very pleased to see the results of our IMM0306 preclinical experimental study being published in the journal Leukemia. IMM0306 is an antibody-receptor recombinant fusion protein (mAb-Trap) targeting both CD47 and CD20. It is the first bispecific molecule targeting CD47/CD20 entered clinical stage globally. IMM0306 does not bind to human erythrocytes in vitro, and preclinical in vivo tests show that the efficacy of IMM0306 is much better than that of rituximab at the similar dose levels. Preliminary clinical trial data from Phase Ia study also demonstrated good safety profile as well as excellent clinical efficacy response due to its unique molecular design. It is promising to expect IMM0306 to take the place of rituximab as the first-line treatment for patients with B-cell lymphoma in the future. We will continue to further expand the clinical trial of the IMM0306 to speed up the launch of IMM0306 to the market to benefit more patients."